WO2005007853A3 - Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics - Google Patents

Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics Download PDF

Info

Publication number
WO2005007853A3
WO2005007853A3 PCT/US2004/018012 US2004018012W WO2005007853A3 WO 2005007853 A3 WO2005007853 A3 WO 2005007853A3 US 2004018012 W US2004018012 W US 2004018012W WO 2005007853 A3 WO2005007853 A3 WO 2005007853A3
Authority
WO
WIPO (PCT)
Prior art keywords
apoptosis
eif
sirnas
inhibition
specific
Prior art date
Application number
PCT/US2004/018012
Other languages
French (fr)
Other versions
WO2005007853A2 (en
Inventor
John E Thompson
Catherine Taylor
Original Assignee
Senesco Technologies Inc
John E Thompson
Catherine Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies Inc, John E Thompson, Catherine Taylor filed Critical Senesco Technologies Inc
Priority to JP2006515257A priority Critical patent/JP5666074B2/en
Priority to CA002528372A priority patent/CA2528372A1/en
Priority to NZ544159A priority patent/NZ544159A/en
Priority to EP04785931A priority patent/EP1636364A2/en
Priority to AU2004258070A priority patent/AU2004258070B2/en
Publication of WO2005007853A2 publication Critical patent/WO2005007853A2/en
Publication of WO2005007853A3 publication Critical patent/WO2005007853A3/en
Priority to IL172365A priority patent/IL172365A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
PCT/US2004/018012 2003-06-06 2004-06-07 Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics WO2005007853A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2006515257A JP5666074B2 (en) 2003-06-06 2004-06-07 Inhibition of apoptosis-specific eIF-5A ("eIF-5A") using antisense oligonucleotides and siRNA as anti-inflammatory therapy
CA002528372A CA2528372A1 (en) 2003-06-06 2004-06-07 Inhibition of apoptosis-specific elf-5a ("eif-5a1") with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics
NZ544159A NZ544159A (en) 2003-06-06 2004-06-07 Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
EP04785931A EP1636364A2 (en) 2003-06-06 2004-06-07 INHIBITION OF APOPTOSIS-SPECIFIC ELF-5A ( EIF-5A1) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS
AU2004258070A AU2004258070B2 (en) 2003-06-06 2004-06-07 Inhibition of apoptosis-specific elF-5A ("elF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
IL172365A IL172365A0 (en) 2003-06-06 2005-12-05 INHIBITON OF APOPTOSIS-SPECIFIC ELF-5A (" EIF-5A1" ) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US47619403P 2003-06-06 2003-06-06
US60/476,194 2003-06-06
US50473103P 2003-09-22 2003-09-22
US60/504,731 2003-09-22
US52824903P 2003-12-10 2003-12-10
US60/528,249 2003-12-10
US55767104P 2004-03-31 2004-03-31
US60/557,671 2004-03-31
US57581404P 2004-06-02 2004-06-02
US60/575,814 2004-06-02

Publications (2)

Publication Number Publication Date
WO2005007853A2 WO2005007853A2 (en) 2005-01-27
WO2005007853A3 true WO2005007853A3 (en) 2005-10-27

Family

ID=34084831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018012 WO2005007853A2 (en) 2003-06-06 2004-06-07 Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics

Country Status (9)

Country Link
EP (1) EP1636364A2 (en)
JP (1) JP5666074B2 (en)
KR (1) KR20060013428A (en)
AU (1) AU2004258070B2 (en)
CA (1) CA2528372A1 (en)
IL (1) IL172365A0 (en)
NZ (2) NZ574973A (en)
TW (1) TW200512293A (en)
WO (1) WO2005007853A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
KR20050098954A (en) 2003-03-05 2005-10-12 세네스코 테크놀로지스 인코포레이티드 Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US20140371299A1 (en) * 2004-06-07 2014-12-18 Senesco Technologies, Inc. Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
WO2006014752A2 (en) * 2004-07-20 2006-02-09 Senesco Technologies, Inc. Use of apoptosis-specific eif-5a sirnas and antisense polynucleotides to inhibit/suppress an inflammatory response
JP2008522591A (en) * 2004-12-03 2008-07-03 セネスコ テクノロジーズ，インコーポレイティド Apoptosis-specific EIF-5A and polynucleotide encoding the same
WO2007070824A2 (en) * 2005-12-13 2007-06-21 Senesco Technologies, Inc. Use of eif-5a to kill multiple myeloma cells
EP1996707A2 (en) * 2006-03-20 2008-12-03 Senesco Technologies, Inc. A novel method of protecting islet cells from apoptosis during the donor harvesting process
CN101605893A (en) * 2006-03-20 2009-12-16 森尼斯科技术公司 The protection islet cells makes it to avoid the novel method of apoptosis during the donor harvesting process
CA2634814A1 (en) * 2006-03-20 2007-09-27 Senesco Technologies, Inc. Use of apoptosis-specific eif-5a sirna to down regulate expression of proinflammatory cytokines to treat sepsis
WO2007115047A2 (en) * 2006-03-29 2007-10-11 Senesco Technologies, Inc. Inhibition of hiv replication and expression of p24 with eif-5a
US20090093434A1 (en) * 2007-08-20 2009-04-09 Senesco Technologies, Inc. Use of eif-5a1 sirna to protect islets cells from apoptosis and to preserve their functionality
AU2009223615B2 (en) 2008-03-07 2014-09-11 Senesco Technologies, Inc. Use of siRNA to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a desired polynucleotide
WO2009144933A1 (en) * 2008-05-27 2009-12-03 国立大学法人東京大学 Apoptosis inducer
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010286A2 (en) * 2001-07-23 2003-02-06 Senesco, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
US20030050272A1 (en) * 2001-07-23 2003-03-13 Catherine Taylor Nucleic acids, polypeptides, and methods for modulating apoptosis
US20030225022A1 (en) * 2001-07-23 2003-12-04 Catherine Taylor Suppression of eIF5A1 expression to prevent retinal ganglion cell death in the glaucomatous eye
WO2004078940A2 (en) * 2003-03-05 2004-09-16 Senesco Technologies, Inc. USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4665196A (en) * 1995-02-13 1996-09-04 Novartis Ag Eukaryotic initiation factor 5A (eIF-5A) mutants
CA2448320A1 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
CA2936534C (en) * 2001-07-23 2021-01-26 The Board Of Trustees Of Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010286A2 (en) * 2001-07-23 2003-02-06 Senesco, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
US20030050272A1 (en) * 2001-07-23 2003-03-13 Catherine Taylor Nucleic acids, polypeptides, and methods for modulating apoptosis
US20030225022A1 (en) * 2001-07-23 2003-12-04 Catherine Taylor Suppression of eIF5A1 expression to prevent retinal ganglion cell death in the glaucomatous eye
WO2003095613A2 (en) * 2002-05-07 2003-11-20 Senesco Technologies, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
WO2004078940A2 (en) * 2003-03-05 2004-09-16 Senesco Technologies, Inc. USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY; NEW ORLEANS, LOUISIANA, USA; APRIL 20-24, 2002 *
CARAGLIA M ET AL: "The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis", AMINO ACIDS (VIENNA), vol. 20, no. 2, 2001, pages 91 - 104, XP002291822, ISSN: 0939-4451 *
CHEN KUANG YU ET AL: "RNA interference analysis of the function of hypusine-containing eukaryotic initiation factor 5A in C. elegans", FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), pages A162, XP008033807, ISSN: 0892-6638 *
RUHL M ET AL: "EUKARYOTIC INITIATION FACTOR 5A IS A CELLULAR TARGET OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REV ACTIVATION DOMAIN MEDIATING TRANS-ACTIVATION", JOURNAL OF CELL BIOLOGY, vol. 123, no. 6, 1 December 1993 (1993-12-01), pages 1309 - 1320, XP000571505, ISSN: 0021-9525 *

Also Published As

Publication number Publication date
JP5666074B2 (en) 2015-02-12
AU2004258070B2 (en) 2008-12-11
WO2005007853A2 (en) 2005-01-27
TW200512293A (en) 2005-04-01
KR20060013428A (en) 2006-02-09
CA2528372A1 (en) 2005-01-27
EP1636364A2 (en) 2006-03-22
NZ574973A (en) 2010-10-29
JP2006526989A (en) 2006-11-30
NZ544159A (en) 2009-04-30
AU2004258070A1 (en) 2005-01-27
IL172365A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
WO2004078940A3 (en) USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
WO2005007853A3 (en) Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics
WO2008078180A3 (en) Materials and methods for the generation of transcripts comprising modified nucleotides
DK1230375T3 (en) Inhibition of gene expression by dsRNA
WO2005118824A8 (en) Methods and compositions for the inhibition of gene expression
WO2005099770A3 (en) Pancreatic islet microrna and methods for inhibiting same
WO2006119266A3 (en) Human micrornas and methods for inhibiting same
WO2003012052A3 (en) Specific inhibition of gene expression by small double stranded rnas
WO2007005645A3 (en) Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
AU2003294440A1 (en) Methods for using riboprimers for strand displacement replication of target sequences
IN2012DN00403A (en)
BRPI0810357A2 (en) METHOD TO INCREASE THE SECRETION OF A POI FROM A EUKARYOTIC CELL, USE OF A NUCLEOTIDE SEQUENCE, NUCLEOTIDE SEQUENCE, YEAST PROMOTING SEQUENCE, EUKARYOTIC EXPRESSION VECTOR, AND USES OF AN EXPRESSION PROMOTER YEAST.
WO2003102214A3 (en) Method for efficient rna interference in mammalian cells
EP1490489A4 (en) Methods and means for monitoring and modulating gene silencing
CY1107772T1 (en) L-RAMNOZE INTERPRETATION EXPRESSION SYSTEMS
WO2006135436A3 (en) Inhibition of gene expression and therapeutic uses thereof
NO20092965L (en) Compositions and Methods to Prevent Cancer with Cupredoxins
WO2005073380A3 (en) Regulated polymerase iii expression systems and related methods
EP1509251A4 (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
WO2006014752A3 (en) Use of apoptosis-specific eif-5a sirnas and antisense polynucleotides to inhibit/suppress an inflammatory response
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
WO2006060823A3 (en) Apoptosis-specific eif-5a and polynucleotides encoding same
WO2007053207A3 (en) Methods for controlling stem cell differentiation
EP1828415A4 (en) Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna
WO2007109674A3 (en) Use of eif-5a1 sirna and antisense to treat sepsis or haemorrhagic shock

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480022528.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2528372

Country of ref document: CA

Ref document number: 172365

Country of ref document: IL

Ref document number: 2006515257

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057023388

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004258070

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 544159

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004785931

Country of ref document: EP

Ref document number: 101/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004258070

Country of ref document: AU

Date of ref document: 20040607

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004258070

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020057023388

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004785931

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)